Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_14216
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 14216
Character Range: 885181–887523

14216                                                                                               Professional attendance on a patient by a psychiatrist, who has undertaken training in Repetitive Transcranial Magnetic Stimulation (rTMS), for treatment mapping for rTMS, if the patient:                                                                                                                                                                                                                                                                                                                                                                                                                               186.40
                                                                                                    (a) has not previously received any prior transcranial magnetic stimulation therapy in a public or private setting; and
                                                                                                    (b) is at least 18 years old; and
                                                                                                    (c) is diagnosed with a major depressive episode; and
                                                                                                    (d) has failed to receive satisfactory improvement for the major depressive episode despite the adequate trialling of at least 2 different classes of antidepressant medications, unless contraindicated, and all of the following apply:
                                                                                                    (i) the patient's adherence to antidepressant treatment has been formally assessed;
                                                                                                    (ii) the trialling of each antidepressant medication has been at the recommended therapeutic dose for a minimum of 3 weeks;
                                                                                                    (iii) where clinically appropriate, the treatment has been titrated to the maximum tolerated therapeutic dose; and
                                                                                                    (e) has undertaken psychological therapy, if clinically appropriate